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Stereodivergent Synthesis of 5-Aminopipecolic Acids and 
Application in the Preparation of a Cyclic RGD Peptidomimetic as 
a nanomolar αVβ3 Integrin Ligand  
Lorenzo Sernissi,a† Luciano Ricci,a Dina Scarpi,a Francesca Bianchini,b Daniela Arosio,c Alessandro 
Contini,*d and Ernesto G. Occhiato*a 
A stereodivergent strategy was devised to obtain enantiopure cis and trans 5-aminopipecolic acids (5-APAs) in suitably 
protected forms to be employed in peptide synthesis as conformationally constrained α- and δ-amino acids. The cis isomer 
was used as a δ-amino acid to construct a cyclic RGD-containing peptidomimetic, the ability of which to compete with 
biotinylated vitronectin for the binding to the isolated αVβ3 integrin was measured (IC50 = 4.2 ± 0.9 nM). A complete 
1H 
NMR and computational conformational analysis was performed to elucidate the reasons for the high affinity of this cyclic 
peptidomimetic in comparison with Cilengitide. 
Introduction 
Integrins are heterodimeric transmembrane receptors for 
extracellular matrix (ECM) proteins which promote adhesion, 
migration, and proliferation of cells by recognizing binding 
motifs in ECM proteins.1 The integrin family that recognizes 
endogenous arginine-glycine-aspartic acid (RGD) ligands are of 
great therapeutic interest, playing a role in thrombosis, 
fibrosis, and cancer. In cancer, integrins mediate adhesion 
events during various stages of the disease, i.e. angiogenesis, 
tumor growth and progression, invasion, and metastasis.2–5 In 
particular, the αVβ3 integrin receptor, which recognizes the 
RGD sequence of vitronectin,6–7 has a critical role in tumor-
induced angiogenesis and metastasis formation.8–13 Therefore, 
RGD-containing peptides and peptidomimetics14–17 as well as 
RGD-mimetics1a are widely studied as antagonists to suppress 
the events mediated by this integrin and as shuttles for 
targeted delivery of drugs and diagnostics.18 
To date, a few low-nanomolar-affinity αVβ3  receptor binders 
which present the RGD system installed on rigid hetero- and 
carbacyclic scaffolds have been reported. For example, bicyclic 
lactams,19–21 γ-aminocyclopentanecarboxylic acids,22 cis-β-
aminocyclopropanecarboxylic acids,23 4-aminoprolines,24,25 
bifunctional diketopiperazines,26 morpholine derivatives,27,28 7-
aminoazocinone-2-carboxylate derivatives,29 and both amino- 
and hydroxy-substituted 2,3-methanopipecolic acids (or CPA, 
cyclopropane pipecolic acid),  the latter recently reported by 
us,30-32 have all been used to generate potent αVβ3 integrin 
ligands. 
Because of our interest in the synthesis33-36 and biomedical 
applications30-32 of pipecolic acid derivatives, in order to 
further expand the array of available scaffolds which can be 
grafted into the key αVβ3-recognizing peptide sequence, we 
decided to synthesize and evaluate 5-aminopipecolic acid, the 
homologue of 4-aminoproline,24,25 as a δ-amino acid on which 
to install the RGD peptide sequence, thus generating new 
cyclic αVβ3 integrin ligands. Pipecolic acid derivatives bearing 
an amino group at position 3, 4 and 5 (Figure 1) are examples 
of endocyclic-Nα/exocyclic-Nβ, -Nγ, and -Nδ constrained basic 
amino acids with a considerable potential in medicinal 
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Figure 1. 3-,4-, and 5-Aminopipecolic Acids 1-6. 
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chemistry not only as α-amino acids with restricted φ, χ1, χ2, 
and/or χ3 torsion angles, but also as rigid β-, γ- or δ-amino 
acids. While some examples of peptidomimetics incorporating 
4-aminopicolic acids 3 and 4 as α-amino acids exist,37,38 their 
regioisomers have rarely been introduced in amino acid 
sequences to generate conformationally restricted peptides or 
embedded in other bioactive compounds, and not many 
efforts have been devoted to their synthesis.39 In particular, 
the synthesis of enantiopure trans 5-aminopipecolic acid 
(herein referred as 5-APA) 5, used as a novel chiral PNA 
monomer, has been reported by Kumar.40 Racemic trans and 
cis 5-APAs (5 and 6) were prepared by Dhimane as new 
conformationally constrained ornithine analogues, as well as 
intermediates for obtaining arginine analogues with 
simultaneous restriction of χi and φ torsion angles.41 Racemic 
cis 5-APA 6 was also prepared by Harris42 and Shono,43 in both 
cases as an intermediate in the synthesis of (±)-Slaframine. 
Therefore, given the paucity of synthetic approaches to 
enantiopure trans and cis 5-APA 5 and 6, and because of our 
interest in the incorporation of cis 5-APA in cyclic RGD ligands, 
we planned a stereodivergent strategy to obtain 5 and 6, 
suitably protected for peptide synthesis, in enantiopure form. 
Results and Discussion 
Chemistry 
We have recently reported an efficient synthesis of both 
enantiomers of 4-hydroxypipecolic acid methyl ester derivative 
7 (Scheme 1) in gram quantities starting from commercial γ-
(hydroxymethyl)butyrolactone 8.35  
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Scheme 1. Retrosynthetic scheme to trans- and cis-5-aminopipecolic acids 9 and 10. 
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Scheme 2. Reagents and conditions: (a) 4 N HCl, reflux; (b) Boc2O, Et3N, MeOH, reflux, 
24 h; (c) K2CO3, BnBr, DMF, 0 °C, then 25 °C, 24 h; (d) MsCl, Et3N, CH2Cl2, -30 °C, then 25 
°C, 2 h; (e) NaN3, DMF, 100 °C, 3 h; (f) H2, 10% Pd/C, MeOH, 25 °C, 24 h; (g) FmocOSu, 
Na2CO3 aq., THF, 0 °C then 25 °C, 16 h. 
In analogy to both Kumar’s40 and Dhimane’s41 syntheses, this 
substrate is suitable to be converted into both trans and cis 5-
APAs 9 and 10 (Scheme 1) by functional and protecting group 
manipulation, although the installation of the orthogonal 
exocyclic N-Fmoc and endocyclic N-Boc groups in trans 5-APA 
9 required a different strategy. 
For the synthesis of protected trans 5-APA 9 (Scheme 2) with S 
absolute configuration at C1, we exhaustively deprotected (1S, 
5S)-7 to obtain free amino acid 11.35 After protection of the N 
atom as N-Boc, benzylation of the carboxylic group provided 
ester 12 in 78% yield over two steps. Mesylation of the OH 
group, followed by nucleophilic displacement by sodium azide 
in DMF provided trans compound 13 in 65% yield (two steps). 
Eventually, hydrogenation over 10% Pd/C provided the free 
amino acid intermediate which was converted into the N-Fmoc 
protected derivative 9 in 63% yield over two steps and with 
orthogonal protection suitable for peptide synthesis. 
For the synthesis of the cis 5-APA, since we wanted to 
introduce it in a cyclic peptide as a δ-amino acid, we decided 
to leave the original protection on the heterocycle N atom 
unaltered (Scheme 3). A first inversion of configuration was 
carried out on 7 by a Mitsunobu reaction which provided trans 
acetate 14. This acetate could not be separated from a by-
product but, after hydrolysis, alcohol 1535 was obtained in 
pure form by chromatography, in 63% yield over two steps. As 
before, the alcohol was converted into azide 16 (73% over two 
steps) and the methyl ester group of the latter hydrolyzed 
under basic conditions to give 17 (100%). This allowed us to 
reduce the azido to amino group without the risk of 
lactamisation during the hydrogenation step.41b The free 
amino acid intermediate was then protected as N-Fmoc 
derivative, furnishing cis 5-APA 10 in 83% yield ready for the 
incorporation into the cyclic peptide. 
The cis relative stereochemistry was easily determined on 
azide 16 by 1H NMR analysis. First, the carboxylic moiety at 
position 2 is axially oriented to remove the A1,3-allylic strain 
present in α-substituted N-acylpiperidines,44 as demonstrated 
by the small coupling constants (< 5.6 Hz) of 2-H with the 
protons at C3. The large coupling constant (12.4 Hz) of 5-H 
with the axially oriented 6-H is in accordance with the 
equatorial orientation of the azido group, which therefore is 
cis to the carboxylic moiety.   
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Scheme 3. Reagents and conditions: (a) Ph3P, DIAD, AcOH, THF, 0 °C, 1 h; (b) MeONa, 
MeOH, 0 °C, 6 h; (c) MsCl, Et3N, CH2Cl2, -30 °C, then 25 °C, 2 h; (d) NaN3, DMF, 100 °C, 3 
h; (e) 1 N NaOH, MeOH, 25 °C, 2 h; (f) H2, 10% Pd/C, MeOH, 25 °C, 24 h; (g) FmocOSu, 
Na2CO3 aq., THF, 0 °C then 25 °C, 16 h. 
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Scheme 4. Reagents and conditions: (a) DEPBT, DIPEA, H-Arg(Mtr)-Gly-OBn, THF, 35 °C, 
4 d; (b) CH2Cl2/DEA 1 : 1, 3 h; (c) DEPBT, DIPEA, Z-Asp(OtBu)-OH, THF, 35 °C, 4 d; (d) H2 
(1 atm), 10% Pd/C, EtOH, 24 h; (e) DEPBT, DIPEA, THF, 35 °C, 4 d; (f) TFA/TIS/H2O 95 : 
2.5 : 2.5, 18 h. 
In alcohol 15 (and in the corresponding mesylate) this coupling 
constant is instead low (< 5 Hz), because of the axial position 
of the substituent at position 5. 
The synthesis of cyclopeptide 22 was carried out in solution 
(Scheme 4) as reported for 4-aminoproline derivatives24 and 4-
amino-substituted cyclopropane pipecolic acids.32 Carboxylic 
acid 10 was coupled to dipeptide H-Arg(Mtr)-Gly-OBn by using 
DEPBT [3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-
one] as the coupling reagent in THF at 35 °C which provided, 
after four days, tripeptide 18 in 98% yield after 
chromatography. Deprotection of the 5-amino group in 18 by 
Et2NH provided compound 19 quantitatively, which was then 
coupled to N-Z,O-tBu-protected aspartic acid as above to give 
tetrapeptide 20 in 50% yield after chromatography. Catalytic 
hydrogenation over 10% Pd/C provided deprotected 
tetrapeptide 21. This, as a crude reaction mixture, was 
subjected to cyclization (4 days) by using DEPBT as the 
coupling reagent in THF (3.5 mM), which furnished 
cyclopeptide 22 after exhaustive deprotection of the 
cyclization intermediate. Semi-preparative HPLC purification 
allowed us to obtain pure 22 (white solid) in 20% yield (over 
the last three steps) as a TFA salt. 
 
Biological Studies 
The RGD-containing peptidomimetic 22 was tested for its 
capacity to compete with vitronectin for the binding to αVβ3 
integrin expressed in high level by M21 human melanoma cells 
as reported,30,32 in comparison to the reference RGD ligand 
cyclo[RGDf(N-Me)V] (Cilengitide)45 (Table 1). 
Table 1. Binding affinity of compound 22 towards integrin αVβ3  
Entry Ligand IC50 (nM) 
  M21 cellsa Isolated αVβ3
b 
1 22 228 ± 128 4.2 ± 0.9 
2 c[RGDf(N-Me)V] (Cilengitide) 3.8 ± 1.7 0.71 ± 0.06c 
3 c[RGDfV] - 2.1 ± 0.9 
a IC50 values were calculated as the concentration of compound required for 50% 
inhibition of integrin-mediated M21 cell adhesion to vitronectin. Experiments 
were conducted in triplicate and all values are the arithmetic mean ± SD. 
b IC50 values were calculated as the concentration of compound required for 50% 
inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism 
software. All values are the arithmetic mean ± SD of duplicate determinations. 
c Ref. 47 
Tests were performed in the presence of 2 mM MnCl2, in order 
to switch integrins of tumor cells into an activated form. The 
ability of compound 22 to compete with biotinylated 
vitronectin for the binding to αVβ3 was also tested towards the 
isolated receptor following a slightly modified procedure 
reported previously,46 in comparison with both Cilengitide and 
cyclo[RGDfV], the parent peptide of Cilengitide. In the cell 
adhesion test, compound 22 was shown to inhibit the binding 
of M21 melanoma cells to vitronectin (IC50 = 228 ± 128 nM) 
but roughly sixty times less than Cilengitide (IC50 = 3.8 ± 1.7 
nM). These data are in agreement with the results obtained in 
the test with the isolated receptor, with a less marked 
difference between the two ligands, that showed for 22 an IC50 
value of 4.2 ± 0.9 nM and for Cilengitide an IC50 value of 0.71 ± 
0.06 nM.47 The comparatively lower inhibition activity of 22 
measured on M21 cell line could be due to the presence of 
other integrins which are inhibited by Cilengitide.17 We have 
already assessed by flow cytometry analysis that the M21 cell 
line, besides high level of αVβ3, expresses also low level (4%) of 
αvβ5 heterodimer.
32 In any case, as will be discussed later, 
these data suggest that the 5-APA structure induces a 
significant conformational asset towards the optimal 
presentation of the pharmacophoric groups of the ligand. 
 
Conformational Analysis 
1
H NMR analysis 
The structure and connectivity of cyclopeptide 22 was 
unambiguously assigned by means of mono- and bi-
dimensional 1H NMR spectroscopy in aqueous solution (8 mM, 
in D2O/H2O 1:9) (all 
1H NMR data are reported in the ESI, Table 
S1) which revealed the presence of two sets of signals in a 
1.4:1 ratio as a consequence of the existence of rotamers 
around the N-CO2Me bond.  
Most data suggest the existence of a preferred conformation 
for ligand 22, even though the temperature coefficient values 
between −5.56 and −8.0 ppb K−1 (Figure S1, ESI) for the N-H 
protons of Asp, Arg and Gly indicate that none of these 
protons is tightly locked in an intramolecular H-bonded state. 
Instead a low coefficient value (-3.56 ppb K-1) for 5-APA-NH 
seems to suggest the involvement of this proton in some H-
bonding. Concerning the six-membered ring, a marked 
distortion of the initial chair after the cyclization, probably 
toward a twist-boat conformation, places the C-5 substituent 
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in a pseudoaxial orientation, as shown by the decreasing  
coupling constant between 6-Hax and 5-H from 12.4 to about 4 
Hz. The analysis of the NOE contacts (see Figure 2) showed the 
presence of medium-strong sequential CHα(i)/NH(i + 1)  
Asp
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Figure 2. NOE correlations in compound 22 
cross-peaks along the Arg-Gly-Asp sequence, although AspNH 
has a NOE cross-peak only with one of the two CHα protons of 
Gly. Two strong contacts, very useful for the determination of 
the putative preferred conformation in solution, were found 
between ArgNH and the CHα of the pipecolic acid (i.e. 2-H) as 
well as with equatorial 3-H of the pipecolic ring, suggesting an 
“outward” orientation of the N–H bond. Moreover, 5-APA-NH 
seems oriented “inward” as it shows a strong cross-peak with 
equatorial 6-H (and a weaker one with 4-H), possibly forming 
an H-bond with the “inward” oriented pipecolic acid C=O 
group, as corroborated by the lowest temperature coefficient 
(−3.56 ppb K−1) for this amide proton. 
As a further indication of the existence of a preferred 
conformation in aqueous solution, the two diastereotopic CHα 
of Gly resonate as highly separated dds (4.04 and 3.50 ppm) 
and, moreover, only one of them (i.e. that at 4.04 ppm) shows 
a cross-peak with the AspNH. 
 
Computational analysis 
The conformational preference of compound 22 was also 
evaluated by replica exchange molecular dynamic (REMD) 
simulations,48 using a previously optimized protocol49 that 
proved to be successful in determining the preferred 
conformation of similar cyclopeptides.30 The simulation 
consisted in 12 replica of 400 ns, with temperatures spanning 
from 300 to 860 K, without using any restraint derived from 
the observed NOE’s. 
Table 2. Population and Selected Dihedrals (deg.) of the Main Conformational Cluster 
of Compound 22 and Cilengitide.a The Corresponding Parameters Measured in the 
Cilengitide-αVβ3 Crystal Structure Are Also Reported for Comparison. 
 22 Cilengitide 
   REMD  crystal 
Pop%  93.3 64.4b / 
φ1 -57.9±9.3 -100.8±23.0 -114.5 
ψ1 119.5±12.8 106.5±25.6 130.5 
φ2 88.1±15.2 91.3±27.3 84.0 
ψ2 -81.3±11.5 -103.1±25.0 -136.2 
φ3 -145.5±10.8 -104.5±29.1 -87.1 
ψ3 77.6±14.6 94.0±16.4 61.4 
dih1 33.0±15.7 / / 
dih2 174.7±9.6 / / 
a Calculated from the cluster analysis of the final 50 ns of the 400 ns REMD 
trajectory obtained at 300 K. 
b Additional conformations found for Cilengitide, together with corresponding 
populations, are shown in Figure S2 (ESI). 
As a comparison, the same protocol was applied to Cilengitide, 
taken as a reference.17 The most representative conformations 
of compound 22 and Cilengitide are shown in Figure 3, while 
selected geometrical parameters are reported in Table 2. 
It can be observed that the obtained conformation for 22 
perfectly matches the putative preferred conformation 
inferred by the NMR analysis (Figure 3A). As suggested by the 
latter, the six-membered ring is in a twist-boat conformation 
and the C5-NH bond is pseudoaxially oriented with the 5-APA-
NH pointing slightly inward (C5-C6-N-H dihedral (dih1) = 
33.0±15.7 deg.) and forming the aforementioned H-bond with 
the pipecolic acid C=O group (d1 = 2.3±0.3 Å). Its distance with 
6-Heq (d2) is 2.6±0.2 Å, and with 4-Heq (d3) is 3.0±0.2 Å, in 
accordance with the NOE correlations and intensities. The CArg-
NArg bond is instead oriented outward (N1-C2-CArg-NArg dihedral 
(dih2) = 174.7±9.6 deg.) with a distance between Arg NH and 
2-H (d4) of 2.5±0.2 Å and between Arg NH and 3-Heq of (d5) 
2.2±0.2 Å, consistently with the NOEs found, with the pipecolic 
acid C=O group forming a dihedral angle of -5.3 deg with the 
C2-N1 bond.  
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Figure 3. Representative conformations of the most populated cluster for compound 22 (panel A) and Cilengitide (panel B). Selected distances and dihedrals are shown accordingly 
to Table 2. 
 
 
Figure 4. Comparison of the root mean squared fluctuations (RMSF) calculated for the 
backbone atoms of the RGD portion of compound 22 (black circle) and cilengitide (red 
diamond). The RMSF was obtained by analyzing a 100 ns MD trajectory obtained from 
the simulation of compound 22 and cilengitide in explicit water. 
All the other distances are in accordance with the NOEs 
correlations (see Table S1, ESI), too. In particular, as found by 
NMR analysis, the AspNH is close to one (the pro-S, accordingly 
to calculations) of the Gly CHα protons (d6 = 2.4±0.2 Å). 
Because of its importance for the biological activity, the 
measured distance between the Cβ atoms of Asp and Arg (d7) 
in the global minimum conformer of 22 resulted in a value of 
8.4±0.2 Å, which is comparable to the corresponding distance 
(8.9 Å) measured in the X-ray structure of the αVβ3-Cilengitide 
complex,50 and very close to the value obtained by REMD 
simulations followed by cluster analysis of Cilengitide (8.5±0.5 
Å) (Figure 3B). Similarly, the analysis of the φ and ψ dihedrals 
belonging to the RGD portion showed a good match between 
compound 22 and Cilengitide in both the free form, obtained 
by REMD, and bound form found in the crystal structure (Table 
2). Interestingly, the lower standard deviations of the 
compared dihedrals and the higher population of the main 
conformational cluster (93.3% vs 64.4% for compound 22 and 
Cilengitide, respectively) suggest that the 5-APA scaffold is 
particularly effective in maintaining the RGD portion rigid and 
close to the bioactive conformation. To confirm this 
observation, we performed 100 ns of classical MD simulation 
in explicit water, starting from the representative 
conformation of the main cluster obtained from the REMD 
simulations of compound 22 and of Cilengitide (in this last 
case, starting from the conformation found in the crystal 
structure provided comparable results). The obtained 
trajectories were processed to perform a root-mean-squared-
fluctuation (RMSF) analysis, which provides a picture of the 
atomic fluctuations during the simulation time and, 
consequently, of the molecule flexibility. A representation of 
the average fluctuations of the backbone atoms of the 
bioactive RGD portions of compound 22 and Cilengitide is 
provided in Figure 4. As expected, it can be observed that 
compound 22 is significantly more rigid, particularly at the Arg 
C=O and Asp Cα and C=O. 
Finally, we ought to evaluate compound 22 in the binding site 
of the αVβ3 receptor. The models were generated starting from 
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the crystal structure of Cilengitide in complex with the αVβ3 
receptor as described in the Experimental section. The 
comparison of the geometries of compound 22 and Cilengitide 
in the binding site of αVβ3 is shown in Figure 5. It can be 
observed that the match between the principal 
pharmacophoric moiety of the two compounds (i.e. the 
sidechains of Arg and Asp) is rather good. In both compounds, 
the Asp carboxylate strongly bind the Mn2+ ion (C=O···Mn2+ 
distance = 2.2 Å) and forms an H-bond with the backbone NH 
of Asn215 (O···H-N distance = 2.3 and 2.1 Å; O···H-N angle = 
174.9 and 174.3 deg. for 22 and Cilengitide, respectively). Two 
strong H-bonds are formed between the guanidine group and 
Asp218 (R-NH···O distance = 1.9 Å for both compounds; R-
NH···O angle = 174.0 and 176.8 deg. for 22 and Cilengitide, 
respectively; C=NH···O distance = 1.8 for both compounds; 
C=NH···O angle = 167.7 and 172.8 deg. for 22 and Cilengitide, 
respectively). It can also be noted that compound 22 misses 
the dispersive interactions between Tyr122 and the benzyl 
group of D-Phe in Cilengitide, which was considered important 
for potency.17,50 However, considering the comparable IC50 
obtained for Cilengitide and compound 22 when tested on the 
isolated αVβ3 integrin receptor, we can gather that the rigidity 
induced by the 5-APA scaffold might be responsible for a 
reduced entropy loss upon binding. Thus, we can speculate 
that future functionalization of the pipecolic ring might lead to 
new αVβ3 ligands with increased potency. 
 
Figure 5. Superposition of compound 22 to the crystal structure of Cilengitide bound to 
αVβ3 integrin receptor. 
Conclusions 
In conclusion, a stereodivergent strategy to obtain 
enantiopure cis and trans 5-aminopipecolic acids (5-APA) in a 
suitably protected form for peptide synthesis has been devised 
starting from known 5-hydroxypipecolic acid as the common 
precursor. The two isomers were efficiently obtained in 38% 
and 32% overall yield, respectively, in seven steps. To 
demonstrate their usefulness in peptidomimetics, the cis 
isomer was embedded as a δ-amino acid in a cyclic RGD-
containing sequence (compound 22). The capacity of 
compound 22 to compete with biotinylated vitronectin for the 
binding to the isolated αVβ3 integrin (IC50 = 4.2 ± 0.9 nM) and 
to that expressed in M21 cells (IC50 = 228 ± 128 nM) was 
measured in comparison with Cilengitide. A conformational 
analysis by both NMR and REMD calculations confirmed that 
the φ and ψ dihedrals of the RGD portion of 22 are in good 
match with those of Cilengitide. Moreover, the 5-APA scaffold 
was shown to be particularly effective in maintaining the RGD 
portion rigid and close to the bioactive conformation. The 
comparison between compound 22 docked to the binding site 
of the αVβ3 receptor and the crystallographic pose of 
Cilengitide resulted in a rather good match between the 
principal pharmacophoric moieties of the two compounds (i.e. 
the sidechains of Arg and Asp). Despite the lack of the 
dispersive interaction presents between integrin’s Tyr122 and 
the benzyl group of D-Phe in Cilengitide, the comparable IC50 
obtained for Cilengitide and compound 22, when tested on the 
isolated αVβ3 integrin receptor, suggests that the rigidity 
induced by the 5-APA scaffold might be responsible for a 
reduced entropy loss upon binding. Thus, we can envisage that 
proper substitutions on the pipecolic ring might lead to new 
αVβ3 ligands with increased potency. 
Experimental 
General Information 
Melting points were recorded on a Büchi B-540 apparatus and 
are uncorrected. Chromatographic separations were 
performed under pressure on silica gel 60 (Merck,70–230 
mesh) by flash-column techniques; Rf values refer to TLC 
carried out on 0.25-mm silica gel plates (Merck F254), with the 
same eluent as indicated for the column chromatography. 1H 
NMR (200, 400, 500 MHz) and 13C NMR (100.4 MHz) spectra 
were recorded either on a Bruker Avance II 500 MHz 
Ultrashield or on a Varian Mercury 400 MHz or on a Varian 
Gemini 200 MHz spectrometers in the specified deuterated 
solvent at 25 °C. Solvent reference lines were set at 7.26 and 
77.00 (CDCl3), 3.31 and 49.00 (CD3OD) in 
1H and 13C NMR 
spectra, respectively. Mass spectra were carried out by direct 
inlet of a 20 ppm solution either in CH3OH or CH3OH + 0.1% 
HCO2H on a LCQ Fleet
TM Ion Trap LC/MS system (Thermo 
Fisher Scientific) with an electrospray ionization (ESI) interface 
in the positive mode. Microanalyses were carried out with a 
CHN Thermo FlashEA 1112 Series elemental analyzer. 
Purification of compound 22 was done by semi-preparative 
HPLC using a Dionex Ulltimate 3000 system equipped with an 
Alltech Alltima C18, 10 μm, 250 mm × 10 mm, reverse-phase 
column, using 5% acetonitrile in water buffered with 0.1% TFA 
as eluent and at a flow rate of 5 mL/min. HPLC analyses were 
carried out on a Dionex Acclaim 120, C18, 5 μm, 4.6 × 250 mm, 
reverse-phase analytical column at a flow rate of 1 mL/min and 
using a water–acetonitrile gradient eluent buffered with 0.1% 
TFA. Signals were monitored at 223 nm with a UV-detector. 
Optical rotations were determined with a JASCO DIP-370 
instrument. Anhydrous solvents were either commercial or 
prepared accordingly to standard techniques. (2S,5S)-5-
Hydroxypipecolic acid hydrochloride (11),35 dimethyl (2S,5S)-5-
hydroxypiperidine-1,2-dicarboxylate (7),35 (2S,5R)-dimethyl 5-
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hydroxypiperidine-1,2-dicarboxylate (15),35 and rac-dimethyl 
5-azidopiperidine-1,2-dicarboxylate (16),41a are known. 
 
Synthesis of (2S,5R)-5-(9-Fluorenylmethoxycarbonylamino)-1-
(tert-butoxycarbonyl)piperidine-2-carboxylic acid [(‒)-9] 
(2S,5S)-2-Benzyl 1- tert-Butyl 5-Hydroxypiperidine-1,2-
dicarboxylate [(-)-12]. To a solution of compound 11 (81 mg, 
0.45 mmol) in anhydrous methanol (10 mL) triethylamine (188 
μL, 1.34 mmol) and Boc2O (197 mg, 0.89 mmol) were added, 
under nitrogen atmosphere, and the resulting reaction mixture 
was heated under reflux. After 24 h, the solvent was 
evaporated under reduced pressure and the residue dissolved 
in H2O (5 mL). NaH2PO4·2H2O (8 mg) was added and the 
resulting solution was cooled to 0 °C, acidified down to pH 3 by 
addition of 0.5 N HCl aqueous solution and then stirred for 30 
min at 0 °C. The product was then extracted with EtOAc (4 x 7 
mL) and the combined organic extracts were dried over 
Na2SO4. After filtration and evaporation of the solvent, the 
crude N-Boc protected intermediate (109 mg) was obtained 
and used in the next step without further purification: 1H NMR 
(200 MHz, CD3OD) (1.1:1 mixture of rotamers) δ (ppm): 4.72 
(br. d, J = 5.2 Hz, 1 H, major), 4.65 (br. d, J = 5.7 Hz, 1 H, minor), 
4.13‒4.02 (m, 1 H, both rotamers), 3.58‒3.42 (m, 1 H, both 
rotamers), 2.78‒2.57 (m, 1 H, both rotamers), 2.36‒2.23 (m, 1 
H, both rotamers), 1.96‒1.89 (m, 1 H, both rotamers), 
1.81‒1.61 (m, 1 H, both rotamers), 1.48 (s, 9 H, minor), 1.43 (s, 
9 H, major), 1.34‒1.12 (m, 1 H, both rotamers). 
To a solution of the N-Boc protected intermediate (109 mg, 
0.45 mmol) and K2CO3 (68 mg, 0.49 mmol) in anhydrous DMF 
(10 mL), cooled at 0 °C and under nitrogen atmosphere, benzyl 
bromide (53 μL, 0.45 mmol) was added. The ice bath was 
removed and the resulting mixture stirred at room 
temperature for 24 h. Water (50 mL) was added, the product 
extracted with EtOAc (25 mL) and the organic extract dried 
over Na2SO4. After filtration and evaporation of the solvent, 
the crude was purified by flash chromatography (n-
hexane/EtOAc, 2:1; Rf 0.23), to afford pure 12 (117 mg, 78%) 
as a white solid: m.p. 69.8-73.7 °C. [α]D
25 –31.8 (c 1.05, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.1:1 mixture of rotamers) δ (ppm): 
7.38‒7.30 (m, 5 H), 5.24‒5.11 (m, 2 H), 4.89 (m, 1 H, major), 
4.70 (m, 1 H, minor), 4.21‒4.18 (m, 1 H, minor), 4.11‒4.08 (m, 
1 H, major), 3.63 (m, 1 H, both rotamers), 2.78‒2.65 (m, 1 H, 
both rotamers), 2.35‒2.26 (m, 1 H, both rotamers), 1.98‒1.94 
(m, 1 H, both rotamers), 1.78‒1.73 (m, 1 H, both rotamers), 
1.45 (s, 9 H, major), 1.37 (s, 9 H, minor). 13C NMR (100.4 MHz, 
CDCl3) (mixture of rotamers) δ (ppm): 171.3, 155.4 and 155.0, 
135.5, 128.5, 128.4 and 128.2, 128.1 and 128.0, 80.5, 66.9, 
66.7 and 66.5, 53.9 and 52.8, 48.4 and 47.5, 30.4 and 29.9, 
28.2 and 28.1, 25.0 and 24.8. MS (ESI) m/z (%): 693 (100) [2M 
+ Na]+, 358 (61) [M + Na]+, 336 (4) [M + 1]+. C18H25NO5 
(335.39): calcd. C 64.46, H 7.51, N 4.18; found C 64.15, H 7.33, 
N 4.10. 
(2S,5R)-2-Benzyl 1- tert-Butyl 5-Hydroxypiperidine-1,2-
dicarboxylate [(-)-13]. Methanesulfonyl chloride (36 μL, 0.45 
mmol) was added dropwise to a solution of 12 (117 mg, 0.35 
mmol) and triethylamine (63 μL, 0.45 mmol) in anhydrous 
CH2Cl2 (3.7 mL), cooled at –30 °C and under nitrogen 
atmosphere. After 5 min the cooling bath was removed and 
the reaction mixture was left under stirring for 2 h at room 
temperature. Water (2 mL) was added followed by a dropwise 
addition of a 0.5 N solution of HCl (1.2 mL) and, after 10 min, 
the product was extracted with CH2Cl2 (3 x 3 mL). The 
combined organic layers were washed with water (3 x 5 mL) 
and dried over Na2SO4. After filtration and evaporation of the 
solvent, the crude was purified by flash chromatography (n-
hexane/Acetone, 1:3; Rf 0.29) to afford the intermediate O-
mesylate (144 mg, quantitative) as a colourless oil: 1H NMR 
(400 MHz, CDCl3) (1.2:1 mixture of rotamers) δ (ppm): 7.42–
7.34 (m, 5 H both rotamers), 5.25–5.12 (m, 3 H, both 
rotamers), 4.92 (d, J = 5.4 Hz, 1 H, major), 4.70 (d, J = 4.8 Hz, 1 
H, minor), 4.61–4.52 (m, 1 H, both rotamers), 4.36 (dd, J = 
12.8, 5.0 Hz, 1 H, minor), 4.25 (dd, J = 12.6, 5.0 Hz, 1 H, major), 
3.03 (s, 3 H, both rotamers), 2.39–2.31 (m, 1 H, both 
rotamers), 2.39–2.31 (m, 1 H, both rotamers), 1.80–1.61 (m, 1 
H, both rotamers), 1.45 (br s, 10 H, major + 1 H, minor), 1.36 
(s, 9 H, minor).  
Sodium azide (170 mg, 2.62 mmol) was added under nitrogen 
atmosphere to a solution of the O-mesylate (144 mg, 0.35 
mmol) in anhydrous DMF (3.2 mL). The mixture was heated to 
100 °C (external) for 3 h, diluted with water (32 mL) and the 
product extracted with Et2O (3 x 32 mL). The combined organic 
extracts were dried over Na2SO4, filtered and the solvent 
evaporated under reduced pressure. The crude residue was 
then purified by flash chromatography (n-hexane/EtOAc, 8:1; 
Rf 0.23) and pure 13 (82 mg, 65%) was obtained as a white 
solid: m.p. 76.5-77.0 °C. [α]D
23 –13.2 (c 0.95, CHCl3). 
1H NMR 
(400 MHz, CDCl3) (1.6:1 mixture of rotamers) δ (ppm): 7.38–
7.30 (m, 5 H, both rotamers), 5.25–5.09 (m, 2 H, both 
rotamers), 5.03 (br s, 1 H, major), 4.78 (br s, 1 H, minor), 4.18–
4.09 (m, 1 H, both rotamers), 3.79 (br s, 1 H, minor), 3.73 (br s, 
1 H, major), 3.24 (d, J = 14.2 Hz, 1 H, major), 3.12 (d, J = 14.7 
Hz, 1 H, minor), 2.08–2.03 (m, 3 H, both rotamers), 1.79–1.73 
(m, 1 H, both rotamers), 1.47 (s, 9 H, major), 1.38 (s, 9 H, 
minor). 13C NMR (100.4 MHz, CDCl3) (major) δ (ppm): 171.2, 
155.3, 135.5, 128.5, 128.2, 128.1, 127.9, 80.7, 66.8, 54.8, 54.2, 
52.9, 44.1, 43.5, 28.1, 24.8, 24.5, 20.9. MS (ESI) m/z (%): 743 
(53) [2M + Na]+, 383 (100) [M + Na]+. C18H24N4O4 (360.18): 
calcd. C 59.99, H 6.71, N 15.55; found C 59.91, H 6.75, N 15.35. 
(2S,5R)-5-(9-Fluorenylmethoxycarbonylamino)-1-(tert-
butoxycarbonyl)piperidine-2-carboxylic acid [(‒)-9]. To a 
solution of 13 (77 mg, 0.21 mmol) in anhydrous MeOH (4 mL), 
10% Pd/C (7 mg, 6.6 µmol) was added under nitrogen 
atmosphere. The resulting suspension was first flushed with 
hydrogen under vigorous stirring and then left under hydrogen 
atmosphere (balloon) at room temperature. After 24 h, the 
mixture was filtered over a celite pad, and the residual 
solution evaporated under reduced pressure. The amino acid 
(52 mg, quantitative) was obtained as a white solid and 
immediately used in the next step without further 
purifications: 1H NMR (400 MHz, CD3OD) δ (ppm): 4.61‒4.50 
(m, 1 H), 3.57‒3.42 (m, 2 H), 2.23‒2.12 (m, 2 H), 1.94‒1.74 (m, 
4 H), 1.45 (s, 9 H). 
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A 10% aqueous solution of Na2CO3 (640 μL) was added to a 
suspension of amino acid (52 mg, 0.21 mmol) in THF (510 μL) 
and the resulting mixture cooled to 0 °C. After the addition of a 
solution of Fmoc-OSu (72 mg, 0.21 mmol) in THF (1.5 mL), the 
ice bath was removed and the mixture was vigorously stirred 
at room temperature for 16 h. The solvent was evaporated 
under reduced pressure and the residue was taken up in EtOAc 
(3 mL). The organic solution was washed once with satd. NH4Cl 
(3 mL) and, after separation of the phases, the aqueous one 
was extracted with EtOAc (5 x 3 mL). The aqueous layer was 
then acidified down to pH 2 by addition of aqueous 0.5 N HCl, 
and extracted again with EtOAc (5 x 3 mL). The combined 
organic extracts were dried over Na2SO4. After filtration and 
evaporation of the solvent, the crude residue was purified by 
flash chromatography (MeOH/CH2Cl2 1:20, Rf 0.14) and pure 
compound 9 (44 mg, 63%) was obtained as a clear syrup: [α]D
23 
–21.7 (c 1.00, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.4:1 mixture 
of rotamers) δ (ppm): 7.77 (d, J = 7.5 Hz, 2 H, both rotamers), 
7.59 (d, J = 7.1 Hz, 2 H, both rotamers), 7.41 (t, J = 7.4 Hz, 2 H, 
both rotamers), 7.32 (t, J = 7.4 Hz, 2 H, both rotamers), 5.17 (br 
s, 1 H, minor), 5.11 (br s, 1 H, major), 4.96 (br s, 1 H, major), 
4.76 (br s, 1 H, minor), 4.51–4.47 (br s, 2 H, minor), 4.42–4.38 
(br s, 2 H, major), 4.23–4.20 (m, 1 H, both rotamers), 4.03–3.88 
(m, 2 H, both rotamers), 3.24–3.15 (m, 1 H, both rotamers), 
2.18–2.03 (m, 1 H, both rotamers), 1.92–1.81 (m, 2 H, both 
rotamers), 1.46 (br s, 10 H, major + 1 H, minor), 1.24 (s, 9 H, 
minor). 13C NMR (100.4 MHz, CDCl3) (major) δ (ppm): 176.4, 
176.2, 156.3, 156.0, 155.6, 143.9, 143.8, 143.7, 143.5, 141.2, 
127.6, 127.0, 124.9, 124.8, 119.9, 119.4, 107.9, 81.1, 67.2, 
66.5, 58.4, 54.4, 53.1, 49.8, 47.2, 46.0, 45.0, 44.6, 31.8, 30.2, 
29.6, 29.3, 29.3, 29.2, 29.0, 28.2, 27.2, 25.0, 24.6, 23.0, 22.6, 
21.0, 20.8, 20.4, 18.2, 14.0. MS (ESI) m/z (%): 954 (9) [2M + 
Na]+, 505 (23) [M + K]+, 489 (100) [M + Na]+. MS (ESI) m/z (%) 
(negative mode): 465 (100) [M – 1]-. C26H30N2O6 (466.53): 
calcd. C 66.94, H 6.48, N 6.00; found C 67.22, H 6.70, N 5.93. 
 
Synthesis of (2S,5S)-5-(9-Fluorenylmethoxycarbonylamino)-1-
(methoxycarbonyl)piperidine-2-carboxylic acid [(–)-10] 
(2S,5R)-Dimethyl 5-Hydroxypiperidine-1,2-dicarboxylate [15]. 
A solution of 7 (372 mg, 1.71 mmol) and Ph3P (673 mg, 2.56 
mmol) in dry THF (13 mL) was added to a solution of 
diisopropyl azodicarboxylate (DIAD) (505 µL, 2.56 mmol) and 
acetic acid (147 µL, 2.56 mmol) in dry THF (13 mL), cooled to 0 
°C and under nitrogen atmosphere. After 1 h, the solvent was 
removed under reduced pressure and the residue taken up in 
a n-hexane-Et2O 1:1 mixture (20 mL). After filtration on a Celite 
pad and evaporation of the solvent, the crude residue was 
purified by flash chromatography (n-hexane/EtOAc, 2:1; Rf 
0.30) to afford acetate 14 (in a 1.2:1 ratio with a residual 
impurity of reduced DIAD) as a colourless oil: 1H NMR (400 
MHz, CDCl3) δ (ppm): 5.08‒4.98 (m, 1 H), 4.93‒4.84 (m, 1 H), 
4.23‒4.07 (m, 1 H), 3.75 (s, 3 H), 3.72 (s, 3 H), 3.31‒3.18 (m, 1 
H), 2.15‒2.01 (m, 2 H), 2.05 (s, 3 H), 1.96‒1.79 (m, 1 H), 
1.61‒1.52 (m, 1 H). 
A solution of 14 in dry MeOH (10 mL) was cooled to 0 °C, under 
nitrogen atmosphere, and MeONa (93 mg, 1.73 mmol) was 
added. After 6 h, glacial acetic acid (769 µL) was added and the 
solvent evaporated. The residue was diluted with water (45 
mL), the product extracted with EtOAc (6 x 60 mL) and the 
combined organic extracts dried over Na2SO4. After filtration 
and evaporation of the solvent, the crude residue was purified 
by flash chromatography (n-hexane/EtOAc, 2:3; Rf 0.18) to 
afford 15 (236 mg, 63% over two steps) as a colourless oil. 
Spectroscopic data are identical to those already reported in 
the literature.35  
(2S,5S)-Dimethyl 5-Azidopiperidine-1,2-dicarboxylate [(–)-16]. 
Prepared as reported for (‒)-13, starting from 15 (236 mg, 1.09 
mmol) and obtaining the intermediate O-mesylate (302 mg, 
94%) after purification by flash chromatography (n-
hexane/EtOAc, 1:1; Rf 0.21) as a colourless oil: 
1H NMR (400 
MHz, CDCl3) (1.2:1 mixture of rotamers) δ (ppm): 5.03 (br s, 1 
H, major), 4.94–4.86 (m, 2 H, major + 1 H, minor), 4.42 (d, J = 
15.0 Hz, 1 H, minor), 4.30 (d, J = 15.0 Hz, 1 H, major), 3.74 (s, 6 
H major + 3 H, minor), 3.72 (s, 3 H, minor), 3.35 (d, J = 15.0 Hz, 
1 H, major), 3.24 (d, J = 15.0 Hz, 1 H, minor), 3.05 (s, 3 H, 
minor), 3.03 (s, 3 H, major), 2.20‒2.04 (m, 3 H, both rotamers), 
1.67‒1.57 (m, 1 H, both rotamers). 
The intermediate O-mesylate was treated with NaN3 as 
reported and pure compound (‒)-16 was obtained as a pale 
yellow oil (192 mg, 78%), after purification by flash 
chromatography (n-hexane/EtOAc, 1:4; Rf 0.18): [α]D
23 –10.2 (c 
1.35, CHCl3). 
Spectroscopic data are identical to those already reported in 
the literature for the corresponding racemic compound.41a  
(2S,5S)-5-Azido-1-(methoxycarbonyl)piperidine-2-carboxylic 
acid [(–)-17]. Aqueous 1 N NaOH (1.19 mL) was added to a 
solution of 16 (192 mg, 0.79 mmol) in methanol (2.3 mL) and 
the resulting mixture was vigorously stirred for 2 h at room 
temperature. The methanol was removed under reduced 
pressure and the residue diluted in water (15 mL). The 
resulting solution was acidified to pH 2 by addition of aqueous 
1 N HCl and the product extracted with CH2Cl2 (3 x 30 mL). The 
aqueous layer was then further acidified to pH 1 and the 
product was extracted again with CH2Cl2 (3 x 30 mL). The 
combined organic extracts were dried over Na2SO4 and, after 
filtration and evaporation of the solvent, compound 17 (181 
mg, quantitative) was obtained as a thick colourless oil: [α]D
23 
–4.4 (c 0.78, CHCl3). 
1H NMR (400 MHz, CDCl3) (1.5:1 mixture of 
rotamers) δ (ppm): 10.70 (bs, 1 H), 4.96 (d, J = 5.3 Hz, 1 H, 
major), 4.81 (d, J = 5.3 Hz, 1 H, minor), 4.32 (dd, J = 12.5, 4.2 
Hz, 1 H, minor), 4.16 (dd, J = 12.5, 4.5 Hz, 1 H, major), 3.75 (s, 3 
H, major), 3.72 (s, 3 H, minor), 3.42–3.31 (m, 1 H, both 
rotamers), 2.86 (t, J = 12.5 Hz, 1 H, major), 2.78 (t, J = 12.5 Hz, 
1 H, minor), 2.43–2.32 (m, 1 H, both rotamers), 2.10–2.01 (m, 
1 H, both rotamers), 1.84–1.73 (m, 1 H, both rotamers), 1.44–
1.31 (m, 1 H, both rotamers). 13C NMR (100.4 MHz, CDCl3) 
(major) δ (ppm): 176.0, 156.7, 56.2, 53.4, 45.4, 29.6, 26.8, 
24.9. MS (ESI) m/z (%): 723 (51) [3M + K]+, 495 (100) [2M + K]+. 
MS (ESI) m/z (%) (negative mode): 227 (100) [M – 1]–. 
C8H12N4O4 (228.21): calcd. C 42.10, H 5.30, N 24.55; found C 
41.88, H 5.65, N 24.10. 
(2S,5S)-5-(9-Fluorenylmethoxycarbonylamino)-1-
(methoxycarbonyl)piperidine-2-carboxylic acid [(–)-10]. 
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Prepared as reported for (‒)-9, starting from 17 (176 mg, 0.77 
mmol) and obtaining the intermediate amino acid (156 mg) as 
a white solid: 1H NMR (400 MHz, CD3OD) (1.1:1 mixture of 
rotamers) δ (ppm): 4.60 (br s, 1 H, minor), 4.51 (br s, 1 H, 
major), 4.18 (d, J = 9.4 Hz, 1 H, both rotamers), 3.70 (br s, 3 H, 
minor), 3.68 (br s, 3 H, major), 3.38–3.25 (m, 1 H, both 
rotamers), 3.21–3.12 (m, 1 H, both rotamers), 2.43–2.31 (m, 1 
H, both rotamers), 2.03–1.95 (m, 1 H, both rotamers), 1.78–
1.66 (m, 1 H, both rotamers), 1.57‒1.46 (m, 1 H, both 
rotamers). MS/MS (ESI of [M + 1]+) m/z (%): 203 (8) [M + 1]+, 
185 (84), 157 (100). 
The intermediate amino acid was treated with Fmoc-OSu as 
reported and pure compound 10 (272 mg, 83%) was obtained 
as a white solid, after purification by flash chromatography 
(MeOH/CH2Cl2 1:10, Rf 0.28): [α]D
19 –16.5  (c 0.70, CH3OH). 
1H 
NMR (400 MHz, CD3OD) (6.5:1 mixture of rotamers) δ (ppm): 
7.77 (d, J = 7.5 Hz, 2 H, both rotamers), 7.62 (d, J = 7.5 Hz, 2 H, 
major), 7.57 (d, J = 7.5 Hz, 2 H, minor), 7.37 (t, J = 7.5 Hz, 2 H, 
both rotamers), 7.29 (t, J = 7.5 Hz, 2 H, both rotamers), 4.64–
4.53 (m, 1 H, both rotamers), 4.50–4.41 (m, 2 H, minor), 4.34 
(br s, 2 H, major), 4.23–4.07 (m, 2 H, both rotamers), 3.66 (s, 3 
H, both rotamers), 3.40 (br s, 1 H, major), 3.14 (br s, 1 H, 
minor), 2.92–2.80 (m, 1 H, both rotamers), 2.42–2.31 (m, 1 H, 
both rotamers), 1.83–1.76 (m, 1 H, both rotamers), 1.70–1.58 
(m, 1 H, both rotamers), 1.38–1.29 (m, 1 H, both rotamers). 13C 
NMR (100.4 MHz, CD3OD) (major) δ (ppm): 178.2, 158.7, 
158.1, 145.3, 142.6, 128.7, 128.1, 126.1, 120.9, 67.6, 53.4, 
48.5, 47.1, 30.7, 28.7, 27.4, 27.2. MS (ESI) m/z (%): 871 (20) 
[2M + Na]+, 447 (100) [M + Na]+. C23H24N2O6 (424.45): calcd. C 
65.08, H 5.70, N 6.60; found C 65.00, H 5.75, N 6.43. 
 
Synthesis of Cyclopeptide 22 
(2S,5S)-5-(9-Fluorenylmethoxycarbonylamino)-1-
(methoxycarbonyl)piperidine-2-Arg(Mtr)-Gly-OBn [(–)-18]. 
DEPBT (334 mg, 1.12 mmol) and DIPEA (194 µL, 1.12 mmol) 
were added under nitrogen atmosphere to a solution of 10 
(237 mg, 0.56 mmol) in anhydrous THF (4 mL) cooled to 0°C, 
and the resulting mixture was allowed to warm to room 
temperature. After 15 min the reaction was cooled again to 
0°C, and H-Arg(Mtr)-Gly-OBn (387 mg, 0.73 mmol) was added. 
The ice bath was removed and the mixture was stirred at 35°C 
(external) for 4 days. The mixture was then diluted with EtOAc 
(90 mL), washed with satd NH4Cl (2 x 23 mL), satd NaHCO3 (2 x 
23 mL), and finally with H2O (2 x 23 mL). The organic extract 
was dried over Na2SO4, filtered, and evaporated under 
reduced pressure. The crude residue was purified by flash 
chromatography (MeOH/CH2Cl2 1:25, Rf 0.23) and pure 18 (514 
mg, 98%) was so obtained as a colourless gummy solid: [α]D
20 –
18.2 (c 0.91, CHCl3). 
1H NMR (400 MHz, CDCl3) (4:1 mixture of 
rotamers) (major) δ (ppm): 7.72 (d, J = 8.0 Hz, 2 H), 7.55 (d, J = 
8.0 Hz, 3 H), 7.36 (t, J = 5.4 Hz, 2 H), 7.31‒7.22 (m, 7 H), 6.49 (s, 
1 H), 6.28 (br s, 4 H), 5.56 (br s, 1 H), 5.09 (s, 2 H), 4.80 (br s, 1 
H), 4.58 (br s, 1 H), 4.37‒4.29 (m, 2 H), 4.19‒3.98 (m, 4 H), 3.79 
(s, 3 H), 3.67 (s, 3 H), 3.67‒3.60 (m, 1 H), 3.36‒3.14 (m, 2 H), 
2.95 (m, 1 H), 2.66 (s, 3 H), 2.59 (s, 3 H), 2.33‒2.25 (m, 1 H), 
2.10 (s, 3 H), 2.34‒2.24 (m, 1 H), 1.88‒1.51 (m, 5 H), 1.47‒1.38 
(m, 1 H). 13C NMR (100.4 MHz, CDCl3) (major) δ (ppm): 175.0, 
172.1, 171.5, 169.8, 158.4, 157.3, 156.5, 155.7, 143.8, 141.1, 
138.3, 136.3, 134.9, 133.1, 128.5, 128.3, 128.1, 127.5, 126.9, 
124.9, 124.8, 119.8, 111.6, 67.0, 66.6, 55.3, 53.2, 49.3, 47.1, 
46.8, 46.2, 41.1, 30.6, 29.5, 25.5, 24.0, 18.3, 17.5, 11.9. MS 
(ESI) m/z (%): 1901 (13) [2M + Na]+, 962 (100) [M + Na]+, 940 
(11) [M + 1]+. C48H57N7O11S (940.07): calcd. C 61.33, H 6.11, N 
10.43; found C 61.51, H 5.95, N 10.35. 
(2S,5S)-5-[Z-Asp(OtBu)]-1-(methoxycarbonyl)-5-APA-2-
Arg(Mtr)-Gly-OBn [(–)-20]. Compound 18 (514 mg, 0.55 mmol) 
was dissolved in a 1:1 CH2Cl2/diethylamine mixture (7 mL) 
under nitrogen atmosphere. The resulting solution was stirred 
at room temperature for 4 h, meanwhile additional 1:1 
CH2Cl2/diethylamine mixture (4 mL) was added. The solution 
was concentrated under reduced pressure, the residue was 
taken up in CH2Cl2 (5 mL) and then concentrated again. The 
crude 19 (584 mg) was obtained as a yellow solid: 1H NMR 
(400 MHz, CDCl3) (5:1 mixture of rotamers) (major) δ (ppm): 
7.52 (br s, 1 H), 7.41‒7.24 (m, 5 H), 6.51 (s, 1 H), 6.36 (br s, 1 
H), 6.33‒6.20 (m, 3 H), 5.12 (s, 2 H), 4.81‒4.50 (m, 2 H), 
4.17‒3.89 (m, 3 H), 3.81 (s, 3 H), 3.67 (s, 3 H), 3.32‒3.12 (m, 3 
H), 2.73‒2.65 (m, 1 H), 2.67 (s, 3 H), 2.60 (s, 3 H), 2.33‒2.21 (m, 
1 H), 2.11 (s, 3 H), 2.03‒1.77 (m, 2 H), 1.77‒1.46 (m, 4 H), 
1.28‒1.22 (m, 1 H). MS (ESI) m/z (%): 740 (9) [M + Na]+, 718 
(100) [M + 1]+. 
DEPBT (433 mg, 1.45 mmol) and DIPEA (253 μL, 1.45 mmol) 
were added under nitrogen atmosphere to a solution of Z-
Asp(OtBu)-OH monohydrate (247 mg, 0.72 mmol) in 
anhydrous THF (8.5 mL), cooled at 0 °C, and the resulting 
mixture was allowed to warm to room temperature. After 15 
min this solution was slowly added to a solution of compound 
19 (0.55 mmol) in anhydrous THF (1 mL) precooled at 0 °C. The 
ice bath was removed and the resulting mixture was stirred at 
35 °C. After 24 h a second portion of Z-Asp(OtBu)-OH 
monohydrate (95 mg, 0.28 mmol), DEPBT (167 mg, 0.56 mmol) 
and DIPEA (97 µL, 0.56 mmol) was added and the mixture 
stirred at 35°C for additional 3 days. The mixture was then 
diluted with EtOAc (90 mL) and washed with satd. NH4Cl (2 x 
25 mL), satd. NaHCO3 (2 x 25 mL) and finally with H2O (2 x 25 
mL). The organic layer was dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude residue was 
purified by flash chromatography (MeOH/CH2Cl2 1:20, Rf 0.24) 
and pure 20 (285 mg, 50%) was obtained as a white solid: 
[α]D
20 –11.4 (c 1.00, CHCl3). 
1H NMR (400 MHz, CDCl3) (8:1 
mixture of rotamers) (major) δ (ppm): 7.48 (br s, 1 H), 
7.38‒7.27 (m, 10 H), 6.84 (br s, 1 H), 6.51 (s, 1 H), 6.27 (br s, 3 
H), 5.97 (m, 1 H), 5.13 (s, 2 H), 5.12‒5.01 (m, 2 H), 4.84‒4.69 
(m, 1 H), 4.63‒4.52 (m, 1 H), 4.51‒4.41 (m, 1 H), 4.14‒3.91 (m, 
3 H), 3.84 (s, 3 H), 3.66 (s, 3 H), 3.31‒3.12 (m, 3 H), 3.04‒2.92 
(m, 1 H), 2.86‒2.71 (m, 1 H), 2.66 (s, 3 H), 2.65‒2.58 (m, 1 H), 
2.59 (s, 3 H), 2.31‒2.21 (m, 1 H), 2.11 (s, 3 H), 1.95‒1.85 (m, 1 
H), 1.84‒1.49 (m, 5 H), 1.46‒1.40 (m, 1 H), 1.39 (s, 9 H). 13C 
NMR (100.4 MHz, CDCl3) (major) δ (ppm): 172.1, 171.6, 170.6, 
170.2, 169.8, 158.5, 157.2, 156.6, 156.0, 138.5, 136.5, 136.1, 
135.2, 135.1, 133.3, 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 
124.9, 111.7, 81.6, 67.2, 67.1, 55.4, 53.7, 53.3, 53.0, 52.9, 51.4, 
45.6, 41.2, 40.4, 37.7, 29.7, 29.6, 28.0, 26.4, 25.4, 24.2, 18.4, 
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12.0. MS (ESI) m/z (%): 1045 (100) [M + Na]+, 1023 (10) [M + 
1]+. C49H66N8O14S·2,5H2O (1068.20): calcd. C 55.10, H 6.70, N 
10.49; found C 55.45, H 6.76, N 10.10. 
Cyclo{Arg-Gly-Asp-[1-(methoxycarbonyl)-5-APA]}·TFA (22). To 
a solution of 20 (282 mg, 0.28 mmol) in ethanol (16 mL), 10% 
Pd/C (138 mg, 0.13 mmol) was added under nitrogen 
atmosphere. The resulting suspension was first flushed with 
hydrogen under vigorous stirring and then left under hydrogen 
atmosphere (balloon) at room temperature. After 18 h, the 
mixture was filtered over a celite pad, and the residual 
solution evaporated under reduced pressure. Compound 21 
(220 mg, 99%) was obtained as a white solid and used in the 
next step without further purifications: 1H NMR (400 MHz, 
CD3OD) δ (ppm): 6.67 (s, 1 H), 4.77 (m, 1 H), 4.41 (dd, J = 8.7, 
4.9 Hz, 1 H), 4.20‒4.10 (m, 1 H), 4.11 (dd, J = 7.9, 4.7 Hz, 1 H), 
3.84 (s, 3 H), 3.80‒3.70 (m, 3 H), 3.71 (s, 3 H), 3.23‒3.15 (m, 2 
H), 2.99‒2.79 (m, 3 H), 2.68 (s, 3 H), 2.62 (s, 3 H), 2.36‒2.32 (m, 
1 H), 2.13 (s, 3 H), 1.91‒1.76 (m, 3 H), 1.75‒1.52 (m, 3 H), 
1.51‒1.43 (m, 1 H), 1.47 (s, 9 H). MS (ESI) m/z (%): 837 (7) [M + 
K]+, 821 (400) [M + Na]+, 799 (100) [M + 1]+. MS (ESI) m/z (%) 
(negative mode): 797 (100) [M – 1]–. 
The crude 21 (218 mg, 0.27 mmol) was suspended in THF (80 
mL) under nitrogen atmosphere. The suspension was cooled to 
0 °C and DEPBT (245 mg, 0.82 mmol) and DIPEA (143 μL, 0.82 
mmol) were added. The resulting mixture was stirred at 35 °C 
for 4 days and then diluted with EtOAc (40 mL); the organic 
solution was washed with satd. NH4Cl (2 x 15 mL), satd. 
NaHCO3 (2 x 15 mL), H2O (2 x 15 mL) and finally dried over 
Na2SO4. After filtration and evaporation of the solvent, the 
residue was eluted through a short pad of silica gel 
(CH2Cl2/MeOH, 25:2) and used directly in the next step: MS 
(ESI) m/z (%): 1583 (23) [2M + Na]+, 819 (21) [M + K]+, 803 
(100) [M + Na]+, 781 (7) [M + 1]+. 
The crude cyclic tetrapeptide was dissolved in a 95:2.5:2.5 
trifluoroacetic acid/triisopropylsilane/H2O mixture (8.4 mL) 
and the resulting solution was stirred at room temperature for 
18 h. The mixture was concentrated under reduced pressure 
and the residue taken up in H2O (10 mL) and washed with Et2O 
(4 x 12 mL). The aqueous layer was then concentrated under 
reduced pressure to afford the deprotected cyclic tetrapeptide 
as a trifluoroacetate salt. This crude was purified by semi-
preparative HPLC (Rt = 13.56 min) and pure 22 (33 mg, 20% 
over 2 steps) was obtained as a colourless glassy solid by 
lyophilization of the HPLC sample. Purity of the final 
compound was checked by analytical HPLC: [α]D
21 +15.2 (c 
0.23, H2O). 
1H NMR (500 MHz, H2O/D2O 9:1) (1.4:1 mixture of 
rotamers) δ (ppm): 8.73‒8.66 (m, 1 H, both rotamers), 8.56 (d, 
J = 12 Hz, 1 H, major), 8.55 (d, J = 12 Hz, 1 H, minor), 8.23 (d, J 
= 8.5 Hz, 1 H, minor), 8.22 (d, J = 8.5 Hz, 1 H, major), 7.96 (d, J = 
9.0 Hz, 1 H, minor), 7.94 (d, J = 9.0 Hz, major), 7.11 (t, J = 6.0 
Hz, 1 H, both rotamers), 4.58‒4.52 (m, 2 H major + 1 H minor), 
4.50 (br s, 1 H, minor), 4.32‒4.22 (m, 1 H, both rotamers), 
4.06‒4.00 (m, 1 H, both rotamers), 4.00‒3.94 (m, 1 H, both 
rotamers), 3.71 (d, J = 13.5 Hz, 1 H, major), 3.68 (d, J = 13.5 Hz, 
1 H, minor), 3.61 (s, 3 H, major), 3.56 (s, 3 H, minor), 3.50 (dd, J 
= 15.0, 4.5 Hz, 1 H, both rotamers), 3.35 (dd, J = 14.0, 4.0 Hz, 1 
H, major), 3.30 (dd, J = 14.0, 4.0 Hz, 1 H, minor), 3.17‒3.11 (m, 
2 H, both rotamers), 2.84 (dd, J = 17.0, 7.0 Hz, 1 H, minor), 2.83 
(dd, J = 17.0, 7.0 Hz, 1 H, major), 2.70 (dd, J = 17.0, 6.0 Hz, 1 H, 
both rotamers), 2.13‒2.00 (m, 3 H, both rotamers), 1.77‒1.57 
(m, 3 H, both botamers), 1.56‒1.46 (m, 1 H, both rotamers), 
1.21‒1.11 (m, 1 H, both rotamers). 13C NMR (100.4 MHz, D2O) 
(mixture of rotamers) δ (ppm): 175.9 and 175.5, 175.3 and 
175.2, 175.0, 170.8 and 170.7, 169.9 and 169.8, 158.4 and 
158.3, 156.7, 55.9 and 55.8, 54.0 and 53.9, 53.2 and 53.1, 49.9 
and 49.8, 44.1, 43.3 and 43.2, 42.7, 40.43 and 40.40, 34.3 and 
34.2, 26.4 and 26.3, 24.3 and 24.2, 23.6 and 23.4, 23.0. MS 
(ESI) m/z (%): 513 (100) [M + 1]+. 
Biological studies 
Materials and methods 
Tests with isolated αvβ3 receptor. Recombinant human 
integrin αvβ3 receptor (R&D Systems, Minneapolis, MN, USA) 
was diluted to 0.5 μg/mL in coating buffer containing 20 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2, 2 mM CaCl2, and 
1 mM MgCl2. An aliquot of diluted receptor (100 μL/well) was 
added to 96-well microtiter plates (Nunc MaxiSorp) and 
incubated overnight at 4 °C. The plates were then incubated 
with blocking solution (coating buffer plus 1% bovine serum 
albumin) for an additional 2 h at room temperature to block 
nonspecific binding. After washing 2 times with blocking 
solution, plates were incubated shaking for 3 h at room 
temperature with various concentrations (10-12 ‒10-5 M) of test 
compound in the presence of 1 μg/mL biotinylated vitronectin 
(Molecular Innovations, Novi, MI, USA). Biotinylation was 
performed using an EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, 
Rockford, IL, USA). After being washed 3 times, the plates were 
incubated shaking for 1 h at room temperature with 
streptavidin biotinylated peroxidase complex (Amersham 
Biosciences, Uppsala, Sweden). Then the plates were washed 
again and finally incubated for 30 min with Substrate Reagent 
Solution (100 µL/well; R&D Systems, Minneapolis, MN), before 
the reaction was stopped by addition of 2 N H2SO4 (50 
µL/well). The absorbance at 415 nm was read in a Synergy HT 
Multi-Detection Microplate Reader (BioTek Instruments, Inc.). 
Each data point is the result of the average of triplicate wells; 
data analysis was carried out by nonlinear regression analysis 
with GraphPad Prism software (GraphPad Prism, San Diego, 
CA). Each experiment was repeated in duplicate. 
 
Tests with M21 Cells.  
Cell lines and culture conditions. The M21 human melanoma 
cell line was obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). Melanoma cells were grown 
in Dulbecco’s modified Eagle medium, containing 4500 mg/L 
glucose (DMEM 4500, GIBCO) supplemented with 10% foetal 
calf serum (FCS) at 37 °C in a humidified incubator containing 
10% CO2. 5.0×10
5 melanoma cells were seeded in 100 mm 
Sarstedt dishes and propagated every 3 days by incubation 
with a trypsin−EDTA solufon. Cultures were periodically 
monitored for mycoplasma contamination. For the use in the 
experiments, cells (passages 2-4) were grown to confluence in 
plates coated with 1% bovine gelatin (Sigma, St. Louis). 
Page 10 of 14Organic & Biomolec lar Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
11
 A
pr
il 
20
18
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i F
ire
nz
e 
on
 1
1/
04
/2
01
8 
13
:0
4:
12
. 
View Article Online
DOI: 10.1039/C8OB00534F
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 11  
Please do not adjust margins 
Please do not adjust margins 
Cell adhesion assay. Plates (96 wells) were coated with 
vitronectin (10 μg/mL) by overnight incubation at 4 °C. Plates 
were washed with PBS and then incubated at 37 °C for 1 h with 
PBS−1% BSA. Ager being washed tumor cells were counted 
and resuspended in serum free medium, and exposed to the 
compound (final concentration was 0.1, 1, and 10 pM, 0.1, 1, 
and 10 nM, 0.1, 1, and 10 μM) at 37 °C for 30 min to allow the 
ligand-receptor equilibrium to be reached. Assays were 
performed in the presence of 2 mmol/L MnCl2. Cells were then 
plated (4−5×104 cells/well) and incubated at 37 °C for 1 h. All 
the wells were washed with PBS to remove the non adherent 
cells, and 0.5% crystal violet solution in 20% methanol was 
added. After 2 h of incubation at 4 °C, plates were examined at 
540 nm in a counter ELX800 (Bio TEK Instruments). 
Experiments were conducted in triplicate and were repeated 
at least three times. The values are expressed as % inhibition ± 
SEM of cell adhesion relative to untreated cells. 
Data Analysis. The IC50 values were determined by fitting 
binding inhibition data by non-linear regression using 
GraphPad Prism 4.0 Software Package (GraphPad Prism, San 
Diego, CA). 
Computational studies   
Material and methods 
Parameterization of nonstandard residues. Charge 
parameterization for (2S,5S)-5-APA, protected at N1 as a 
methyl carbamate, was performed using the R.E.D. 
procedure.51 The structure was capped by a acetyl and a 
NHMe at the 5-amino and at the C-2 carboxy group, 
respectively, and subjected to a conformational search using 
the low mode method and the MMFF94x force field, 
implemented in MOE (other parameters were left as 
default).52 The two lowest energy conformations were used for 
charge parameterization. Moreover, for each conformation, 
two different orientations were used to derive RESP charges. 
The Gaussian09 software was used for quantum mechanical 
calculations,53 at the HF/6-31G* level, as requested for force 
field compatibility. 
REMD simulations. Starting conformations of compound 22 
were generated by a preliminary conformational search 
performed with MOE.52  Independent REMD runs were started 
from two different conformations, selected to maximize 
geometrical difference. The ff96 force field coupled with the 
GB-OBC(II) solvent model54 was adopted accordingly to a 
protocol previously applied to similar synthetic peptides.30,49d 
Geometries were minimized by 500 steps of steepest-
descendant followed by 500 steps of conjugated-gradient and 
twelve replicas were run at 300.00, 330.69, 364.36, 401.31, 
441.89, 486.42, 535.31, 588.95, 647.82, 712.41, 783.26, and 
860.93 K. After a short equilibration (200 ps), production runs 
were conducted for 400 ns at constant temperature, using the 
Langevin thermostat with a collision frequency of with a 
collision frequency of 1.0 ps-1.55 A time step of 0.002 ps and an 
infinite cut-off for electrostatic were adopted. Exchanges were 
attempted every 2 ps and an acceptance rate above 50% was 
observed. To evaluate convergence, the 300 K trajectories 
were subjected to a cluster analysis every 50 ns. The 
simulation was considered converged when the population of 
the three principal clusters differed by less than 15% between 
consecutive 50 ns batches. After 300 ns of simulation, no 
significant differences were observed in the population of the 
three main clusters and in their representative geometries. 
Moreover, no significant differences were observed between 
results obtained by independent simulations starting from 
divergent geometries. REMD calculations and cluster analyses 
were performed with the pmemd.MPI and cpptraj executables 
of the Amber16/AmberTools17 packages, respectively.56 A 
maximum of 10 clusters was requested, using the average-
linkage algorithm, the pairwise mass-weighted RMSD on 
backbone heavy atoms as a metric and sampling one frame 
every 4 ps. 
MD simulations. Classical MD simulations were performed by 
starting from the reference geometry of the most populated 
cluster, as obtained from cluster analysis. In the case of 
Cilengitide, the simulations were also repeated by starting 
from the crystal structure reported in ref. 50. The system was 
prepared using tleap, setting an octahedral solvent box of 
TIP3P water extending up to 10 Å from the solute. Volume and 
density were equilibrated trough subsequent NVT (100 ps) and 
NPT (100 ps) simulations, where the solute was kept 
restrained. The system was then geometry minimized and 
gently heated up to the final temperature of 300 K. Further 
equilibration was performed by NVT (200 ps) and NPT (1000 
ps) simulations, where solute restraints were gradually 
removed. A NVT production run of 100 ns was then performed 
using a cutoff of 8 Å was for electrostatics and PME for long-
range interactions.57 All bonds involving hydrogens atoms 
were constrained by using the SHAKE algorithm.58 Production 
runs were performed on a GPU card using the pmemd.cuda 
engine59 and trajectories were analyzed using cpptraj 
(AmberTools17).56 
Modelling of ligand-receptor complexes. The ligand-receptor 
models for compound 22 and Cilengitide were obtained with 
MOE52 starting from the 1L5G pdb file.50 Only chains B (the 
receptor monomer) and C (Cilengitide) were maintained and 
the structure was processed with the Structure Preparation 
module and protonated accordingly to a pH = 7. The 
representative geometry of compound 22, as obtained by 
REMD simulations followed by cluster analysis, was manually 
docked to αVβ3 by superposing the Cα of the RGD portion to 
the corresponding atoms of the co-crystallized Cilengitide, that 
was then removed. The resulting geometry was then 
minimized up to a gradient of 0.1 kcal/mol/Å2, using the 
Amber10EHT force field and the Born solvation model for 
water, keeping the receptor backbone atoms restrained. For 
comparison, the same protocol was applied to the complex of 
Cilengitide. 
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